Novavax vaccine – faster and better than predicted

NOVAVAX INC surprises and overtakes competitors by announcing that in January it will be possible to start the commercial production of a COVID-19 vaccine adapted to the #Omicron variant of the coronavirus.


Novavax and Omicron

Novavax will begin testing whether antibodies from previously vaccinated individuals can neutralize the Omicron variant, with lab data expected in the coming weeks. Additionally, they plan to test whether the antibodies of the vaccinated can block the binding of the Omicron-hACE2 receptor (a step required in the viral invasion process).


Omicron and SARS-CoV-2

In parallel, Novavax initiated the development of an Omicron-specific construct of its SARS-CoV-2 (rS) spike antigen, currently used in NVX-CoV2373.

Find out more:,